Reduced platelet forces underlie impaired hemostasis in mouse models of MYH9-related disease

Area of Science:

• Hematology
• Molecular Biology
• Biophysics

Background:

• MYH9-related disease is characterized by macrothrombocytopenia and bleeding.
• Mutations in the nonmuscle myosin heavy chain IIA (MYH9) gene are implicated.
• The mechanisms behind the increased bleeding risk require further investigation.

Purpose of the Study:

• To investigate the mechanisms underlying the increased bleeding risk in MYH9-related disease.
• To evaluate the therapeutic potential of tranexamic acid in restoring hemostatic function.

Main Methods:

• Utilized three mouse lines with specific point mutations in the Myh9 gene.
• Assessed platelet activation, myosin light chain phosphorylation, and biophysical characteristics.
• Measured adhesion, interaction, and traction forces of mutant platelets.
• Evaluated the effect of tranexamic acid on clot retraction and bleeding in mouse models.
• Verified findings using platelets from MYH9-related disease patients.

Main Results:

• Agonist-induced platelet activation was comparable between mutant and control mice.
• Reduced myosin light chain phosphorylation was observed in Myh9 mutant platelets.
• Mutant platelets exhibited altered biophysical properties, leading to decreased adhesion and traction forces.
• Tranexamic acid treatment successfully restored clot retraction and reduced bleeding.
• Findings in mouse models were corroborated by studies on patient-derived platelets.

Conclusions:

• Reduced platelet forces contribute significantly to the bleeding tendency in MYH9-related disease.
• Tranexamic acid demonstrates potential as a therapeutic agent to improve hemostasis in these patients.